Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
IMTX Stock Chart & Stats
$9.43
<$0.01(0.14%)
At close: 4:00 PM EST
$9.43
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$3.30 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)519.31K
Market Cap
$1.26B
Enterprise Value$764.93M
Total Cash (Recent Filing)$469.14M
Total Debt (Recent Filing)$15.63M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 19, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding134,063,830
10 Day Avg. Volume826,968
30 Day Avg. Volume519,308
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue15.85
Enterprise Value/Gross Profit15.85
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$20.17Price Target Upside113.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$40.33M
Bulls Say, Bears Say
Bulls Say
PRAME Franchise Leadership & Pipeline BreadthImmatics' concentrated PRAME franchise (anzu-cel Phase 3, IMA203CD8, IMA402) creates a durable competitive position in a defined antigen target set. Multiple modalities and staged indications reduce single-program risk and increase odds of commercial success across solid tumors if pivotal readouts and approvals succeed.
Strengthened Balance Sheet And Material Cash ReservesA sizable cash position and low leverage provide multi-year funding visibility for late‑stage development, regulatory filing prep and early commercialization activities. This materially lowers near‑term refinancing risk and supports executing Phase 3/SUPRAME milestones and planned indication expansions.
Strategic Partnerships And External ValidationPartnerships (e.g., Moderna collaboration) validate Immatics' platform, spread R&D cost and provide development/commercial expertise. Such alliances can accelerate trials, enable combination strategies, and strengthen go‑to‑market potential—improving resource efficiency and strategic optionality over multiple years.
Bears Say
Ongoing Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow in 2024–2025 demonstrates ongoing burn to fund trials and R&D. Even with material cash, continued high burn erodes reserves, increasing the probability of future equity raises or partnership dependence, which can dilute shareholders and distract management.
Sharp Revenue Decline And Earnings VolatilityA steep revenue drop and a swing to a large net loss in 2025 highlight volatile commercial and collaboration receipts. This inconsistency undermines predictability of margins and return on invested capital, complicating planning and increasing reliance on milestone timing for near‑term financial stability.
Business Model Dependency On Clinical And Regulatory SuccessAs a clinical‑stage biotech, Immatics' future revenue depends on successful trials, regulatory approvals and milestone captures. Clinical setbacks, delays or unfavorable readouts can materially reduce near‑term cash inflows and force dilution or cutbacks, making execution risk central to long‑term value realization.
Immatics News
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $3.30 and its highest was $12.41 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $1.26B.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is May 19, 2026 which is in 57 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Mar 05, 2026. The company reported -$0.324 earnings per share for the quarter, beating the consensus estimate of -$0.476 by $0.153.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.44.
How many shares outstanding does Immatics have?
Immatics has 134,063,830 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.324 in its last earnings report, beating expectations of -$0.476. Following the earnings report the stock price went down -0.295%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.17 (113.89% Upside)
$20.17 (113.89% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 178.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.92%
12-Months-Change
Fundamentals
Return on Equity
-39.69%
Trailing 12-Months
Asset Growth
-8.38%
Trailing 12-Months
Company Description
Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Stock 12 Month Forecast
Average Price Target
$20.17
▲(113.89% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.90% Mutual Funds
49.42% Other Institutional Investors
39.18% Public Companies and
Individual Investors